Page 1721 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 95 Practical Aspects of Hematologic Stem Cell Harvesting and Mobilization 1530.e1

REFERENCES 17. Lee SJ, Kamani N, Confer DL: Principles and tools for selection of
umbilical cord blood and unrelated adult donors grafts. Biol Blood
1. Beyer J, Schwella N, Zingsem J, et al: Hematopoietic rescue after Marrow Transplant 14(1 Suppl 1):112–119, 2008.
high-dose chemotherapy using autologous peripheral-blood pro- 18. Bray RA, Hurley CK, Kamani NR, et al: National Marrow Donor
genitor cells or bone marrow: a randomized comparison. J Clin Oncol Program HLA matching guidelines for unrelated adult donor
13(6):1328–1335, 1995. hematopoietic cell transplants. Biol Blood Marrow Transplant 14(9
2. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim- Suppl):45–53, 2008.
mobilised peripheral blood progenitor cell transplantation versus 19. Loren AW, Bunin GR, Boudreau C, et al: Impact of donor and recipi-
autologous bone-marrow transplantation in lymphoma patients. Lancet ent sex and parity on outcomes of HLA-identical sibling allogeneic
347(8998):353–357, 1996. hematopoietic stem cell transplantation. Biol Blood Marrow Transplant
3. Hartmann O, Le Corroller AG, Blaise D, et al: Peripheral blood stem 12(7):758–769, 2006.
cell and bone marrow transplantation for solid tumors and lymphomas: 20. Farag SS, Bacigalupo A, Eapen M, et al: The effect of KIR ligand
hematologic recovery and costs. A randomized, controlled trial. Ann incompatibility on the outcome of unrelated donor transplantation: a
Intern Med 126(8):600–607, 1997. report from the Center for International Blood and Marrow Transplant
4. Smith TJ, Hillner BE, Schmitz N, et al: Economic analysis of a ran- Research, the European Blood and Marrow Transplant Registry, and the
domized clinical trial to compare filgrastim-mobilized peripheral-blood Dutch Registry. Biol Blood Marrow Transplant 12(8):876–884, 2006.
progenitor-cell transplantation and autologous bone marrow transplan- 21. Rowley SD, Donato ML, Bhattacharyya P: Red blood cell-incompatible
tation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin hematopoietic progenitor cell transplantation. Bone Marrow Transplant
Oncol 15(1):5–10, 1997. 46(9):1167–1185, 2011.
5. Vellenga E, van Agthoven M, Croockewit AJ, et al: Autologous 22. Horowitz MM, Confer DL: Evaluation of hematopoietic stem cell
peripheral blood stem cell transplantation in patients with relapsed donors. Hematology Am Soc Hematol Educ Program 469–475, 2005.
lymphoma results in accelerated haematopoietic reconstitution, 23. Sacchi N, Costeas P, Hartwell L, et al: Haematopoietic stem cell donor
improved quality of life and cost reduction compared with bone marrow registries: World Marrow Donor Association recommendations for
transplantation: the Hovon 22 study. Br J Haematol 114(2):319–326, evaluation of donor health. Bone Marrow Transplant 42(1):9–14, 2008.
2001. 24. Confer DL, Shaw BE, Pamphilon DH: WMDA guidelines for
6. van Agthoven M, Vellenga E, Fibbe WE, et al: Cost analysis and subsequent donations following initial BM or PBSCs. Bone Marrow
quality of life assessment comparing patients undergoing autologous Transplant 46(11):1409–1412, 2011.
peripheral blood stem cell transplantation or autologous bone marrow 25. Pamphilon D, Siddiq S, Brunskill S, et al: Stem cell donation—
transplantation for refractory or relapsed non-Hodgkin’s lymphoma What advice can be given to the donor? Br J Haematol 147(1):71–76,
or Hodgkin’s disease. A prospective randomised trial. Eur J Cancer 2009.
37(14):1781–1789, 2001. 26. Worel N, Buser A, Greinix HT, et al: Suitability criteria for adult related
7. Lown RN, Tulpule S, Russell NH, et al: Subsequent donation requests donors: a consensus statement from the Worldwide Network for Blood
among 2472 unrelated hematopoietic progenitor cell donors are and Marrow Transplantation (WBMT) Standing Committee on Donor
associated with bone marrow harvest. Haematologica 98:1956–1963, Issues. Biol Blood Marrow Transplant 2015. [Epub ahead of print].
2013. 27. Niederwieser DW, Appelbaum FR, Gastl G, et al: Inadvertent transmis-
8. Blaise D, Kuentz M, Fortanier C, et al: Randomized trial of bone sion of a donor’s acute myeloid leukemia in bone marrow transplantation
marrow versus lenograstim-primed blood cell allogeneic transplanta- for chronic myelocytic leukemia. N Engl J Med 322(25):1794–1796,
tion in patients with early-stage leukemia: a report from the Societe 1990.
Francaise de Greffe de Moelle. J Clin Oncol 18(3):537–546, 2000. 28. Buell JF, Beebe TM, Trofe J, et al: Donor transmitted malignancies.
9. Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow Ann Transplant 9(1):53–56, 2004.
as compared with peripheral-blood cells from HLA-identical relatives 29. O’Donnell PV, Pedersen TL, Confer DL, et al: Practice patterns
in patients with hematologic cancers. N Engl J Med 344(3):175–181, for evaluation, consent, and care of related donors and recipients at
2001. hematopoietic cell transplantation centers in the United States. Blood
10. Couban S, Simpson DR, Barnett MJ, et al: A randomized multicenter 115(24):5097–5101, 2010.
comparison of bone marrow and peripheral blood in recipients of 30. Anderlini P, Przepiorka D, Seong D, et al: Clinical toxicity and
matched sibling allogeneic transplants for myeloid malignancies. Blood laboratory effects of granulocyte-colony-stimulating factor (filgrastim)
100(5):1525–1531, 2002. mobilization and blood stem cell apheresis from normal donors, and
11. Schmitz N, Beksac M, Hasenclever D, et al: Transplantation of mobi- analysis of charges for the procedure. Transfusion 36(7):590–595, 1996.
lized peripheral blood cells to HLA-identical siblings with standard-risk 31. Kurtzberg J, Cairo MS, Fraser JK, et al: Results of the Cord Blood
leukemia. Blood 100(3):761–767, 2002. Transplantation (COBLT) Study unrelated donor banking program.
12. Morton J, Hutchins C, Durrant S: Granulocyte-colony-stimulating Transfusion 45(6):842–855, 2005.
factor (G-CSF)-primed allogeneic bone marrow: significantly less graft- 32. Shaw BE, Logan BR, Kiefer DM, et al: An analysis of the effect of
versus-host disease and comparable engraftment to G-CSF-mobilized race, socioeconomic status and center size on unrelated NMDP donor
peripheral blood stem cells. Blood 98(12):3186–3191, 2001. outcomes: donor toxicities are more common at low volume bone
13. Frangoul H, Nemecek ER, Billheimer D, et al: A prospective study of marrow collection centers. Biol Blood Marrow Transplant 2015. [Epub
G-CSF-primed bone marrow as a stem-cell source for allogeneic bone ahead of publication].
marrow transplantation in children: a Pediatric Blood and Marrow 33. Wang TF, Chu SC, Chen SH, et al: The effect of different harvest
Transplant Consortium (PBMTC) study. Blood 110(13):4584–4587, strategies on the nucleated cell yields of bone marrow collection. Biol
2007. Blood Marrow Transplant 17(3):351–355, 2011.
14. Damiani D, Fanin R, Silvestri F, et al: Randomized trial of autologous 34. Bacigalupo A, Tong J, Podesta M, et al: Bone marrow harvest for
filgrastim-primed bone marrow transplantation versus filgrastim- marrow transplantation: effect of multiple small (2 ml) or large (20 ml)
mobilized peripheral blood stem cell transplantation in lymphoma aspirates. Bone Marrow Transplant 9:467–470, 1992.
patients. Blood 90:36, 1997. 35. Zeller W, Hesse I, Dürken M, et al: Increasing the yield of harvested
15. Auberger J, Clausen J, Kircher B, et al: Allogeneic bone marrow vs. bone marrow cells by raising room temperature during marrow collec-
peripheral blood stem cell transplantation: a long-term retrospective tion. Exp Hematol 23:1527–1529, 1995.
single-center analysis in 329 patients. Eur J Haematol 87(6):531–538, 36. Edgcombe H, Carter K, Yarrow S: Anaesthesia in the prone position.
2011. Br J Anaesth 100:165–183, 2008.
16. Barker JN: Umbilical cord blood (UCB) transplantation: an alternative 37. Miller JP, Perry EH, Price TH, et al: Recovery and safety profiles of
to the use of unrelated volunteer donors? Hematology Am Soc Hematol marrow and PBSC donors: experience of the National Marrow Donor
Educ Program 55–61, 2007. Program. Biol Blood Marrow Transplant 14(9 Suppl):29–36, 2008.